DUAL- VERSUS MONO-ANTIPLATELET THERAPY IN PATIENTS UNDERGOING TAVR: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDIES

DUAL- VERSUS MONO-ANTIPLATELET THERAPY IN PATIENTS UNDERGOING TAVR: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDIES

Background Current guidelines recommend dual-antiplatelet strategy (DAPT) following transcatheter aortic valve replacement (TAVR), however some studies have suggested that mono-antiplatelet strategy (MAPT) may be equally efficacious with an improved safety profile. In patients undergoing TAVR, DAPT...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2018-03, Vol.71 (11), p.A1284-A1284
Hauptverfasser: Halabi, Shadi Al, Newman, Joshua, Farkouh, Michael E., Fortuin, David, Leya, Ferdinand, Sweeney, John, Webb, John, Lopez, John, Steen, Lowell, Lewis, Bruce, Darki, Amir, Mathew, Verghese
Format: Artikel
Sprache:eng
Schlagworte:
Bleeding
Clinical trials
Health risk assessment
Mortality
Myocardial infarction
Observational studies
Stroke
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Current guidelines recommend dual-antiplatelet strategy (DAPT) following transcatheter aortic valve replacement (TAVR), however some studies have suggested that mono-antiplatelet strategy (MAPT) may be equally efficacious with an improved safety profile. In patients undergoing TAVR, DAPT use was associated with increased 30 day risk of the primary endpoint of death, myocardial infarction, stroke or TIA, and major or life threatening bleeding (RR 2.11 95% CI: 1.39, 3.21; p
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(18)31825-4